{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010873","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.833701+00:00","generated_at":"2026-05-24T11:40:28.801058+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glucotrack to present first-in-human CBGM trial data at ATTD 2025 conference in Amsterdam","bullets":["Safety and performance data from first-in-human trial of implantable CBGM system to be presented at ATTD conference, March 19-22, 2025.","Device measures glucose directly from blood, not interstitial fluid, with no on-body wearables, designed for 3-year continuous monitoring.","Trial is an early feasibility study in adults with diabetes; results support advancement to chronic implant study.","CEO Paul Goode highlights potentially transformative advancement in diabetes management."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010873","json":"https://secwatch.observer/filing/0001493152-25-010873.json","markdown":"https://secwatch.observer/filing/0001493152-25-010873.md","text":"https://secwatch.observer/filing/0001493152-25-010873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315225010873/0001493152-25-010873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315225010873/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:40:28.801058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}